title: Massively parallel sequencing of maternal plasma DNA in 113 cases of fetal nuchal cystic hygroma.
abstract: OBJECTIVE
  To estimate the accuracy and potential clinical effect of using massively parallel sequencing of maternal plasma DNA to detect fetal aneuploidy in a cohort of pregnant women carrying fetuses with nuchal cystic hygroma.
  
  
  METHODS
  The MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) study database was queried to identify eligible patients carrying fetuses with cystic hygroma (n=113) based on clinical ultrasonographic examination reports near enrollment. Archived plasma samples were newly sequenced and normalized chromosome values were determined. Aneuploidy classifications for chromosomes 21, 18, 13, and X were made using the massively parallel sequencing data by laboratory personnel blinded to fetal karyotype and compared for analysis.
  
  
  RESULTS
  : Sixty-nine of 113 (61%) patients had fetuses with abnormal karyotypes, including trisomy 21 (n=30), monosomy X (n=21), trisomy 18 (n=10), trisomy 13 (n=4), and other (n=4). There were 44 euploid cases; none was called positive for aneuploidy. The massively parallel sequencing detection rates were as follows: T21: 30 of 30, T18: 10 of 10, T13: three of four, and monosomy X: 20 of 21, including two complex mosaic cases. Overall, using massively parallel sequencing results of the four studied chromosomes, 107 of 113 (95%, 95% confidence interval [CI] 88.8-98.0) cases were accurately called by massively parallel sequencing, including 63 of 65 (97%, 95% CI 89.3-99.6) of cases of whole chromosome aneuploidy.
  
  
  CONCLUSIONS
  : Massively parallel sequencing provides an accurate way of detecting the most prevalent aneuploidies associated with cystic hygroma. Massively parallel sequencing could advance prenatal care by providing alternative point-of-care noninvasive testing for pregnant women who either decline or do not have access to an invasive procedure.
  
  
  BACKGROUND
  ClinicalTrials.gov, www.clinicaltrials.gov, NCT01122524.
  
  
  METHODS
  II.
authors: Mother Infant Research Institute at Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts; the Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota Medical School, Minneapolis, Minnesota; the Center for Fetal Medicine and Women's Ultrasound and the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California; the Prenatal Diagnosis Center, San Francisco Perinatal Associates, San Francisco, California; Eastern Virginia Medical School, Norfolk, Virginia; and Verinata Health, Inc, Redwood City, California.
authors: Diana W
authors: DW
authors: Bianchi
authors: Tracy
authors: T
authors: Prosen
authors: Lawrence D
authors: LD
authors: Platt
authors: James D
authors: JD
authors: Goldberg
authors: Alfred Z
authors: AZ
authors: Abuhamad
authors: Richard P
authors: RP
authors: Rava
authors: Amy J
authors: AJ
authors: Sehnert
mesh_terms: D000293:Adolescent; D000328:Adult; D004273:DNA, Neoplasm / Q000097:blood*; D005260:Female; D005315:Fetal Diseases / Q000235:genetics*; D006258:Head and Neck Neoplasms / Q000235:genetics*; D006801:Humans; D018191:Lymphangioma, Cystic / Q000235:genetics*; D011247:Pregnancy; D017422:Sequence Analysis, DNA / Q000379:methods; D055815:Young Adult
chemical_list: D004273:DNA, Neoplasm
references: Malone FD, Ball RH, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, et al.. First-trimester septated cystic hygroma: prevalence, natural history, and pediatric outcome. Obstet Gynecol 2005;106:288–94.
references: Scholl J, Durfee SM, Russell MA, Heard AJ, Iyer C, Alammari R, et al.. First-trimester cystic hygroma: relationship of nuchal translucency thickness and outcomes. Obstet Gynecol 2012;120:551–9.
references: Chervenak FA, Isaacson G, Blakemore KJ, Breg WR, Hobbins JC, Berkowitz RL, et al.. Fetal cystic hygroma. Cause and natural history. N Engl J Med 1983;309:822–5.
references: Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal BLood IS Source to Accurate diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890–901.
references: Sehnert AJ, Rhees B, Comstock D, de Feo F, Heilek G, Burke J, et al.. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011;57:1042–9.
references: Ralston SJ, Wertz D, Chelmow D, Craigo SD, Bianchi DW. Pregnancy outcomes after prenatal diagnosis of aneuploidy. Obstet Gynecol 2001;97:729–33.
references: Singh RP, Carr DH. The anatomy and histology of XO human embryos and fetuses. Anat Rec 1966;155:369–83.